These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16394018)

  • 1. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells.
    Trenado A; Sudres M; Tang Q; Maury S; Charlotte F; Grégoire S; Bonyhadi M; Klatzmann D; Salomon BL; Cohen JL
    J Immunol; 2006 Jan; 176(2):1266-73. PubMed ID: 16394018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
    Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
    Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
    Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
    Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
    Giorgini A; Noble A
    J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
    Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.
    Sugiyama H; Maeda Y; Nishimori H; Yamasuji Y; Matsuoka K; Fujii N; Kondo E; Shinagawa K; Tanaka T; Takeuchi K; Teshima T; Tanimoto M
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):183-91. PubMed ID: 24333142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
    Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
    Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
    Pillai AB; George TI; Dutt S; Strober S
    Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.
    Vogtenhuber C; Bucher C; Highfill SL; Koch LK; Goren E; Panoskaltsis-Mortari A; Taylor PA; Farrar MA; Blazar BR
    Blood; 2010 Jul; 116(3):466-74. PubMed ID: 20442366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.
    Tawara I; Shlomchik WD; Jones A; Zou W; Nieves E; Liu C; Toubai T; Duran-Struuck R; Sun Y; Clouthier SG; Evers R; Lowler KP; Levy RB; Reddy P
    J Immunol; 2010 Oct; 185(7):3866-72. PubMed ID: 20810991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
    Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
    Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.
    Ma H; Lu C; Ziegler J; Liu A; Sepulveda A; Okada H; Lentzsch S; Mapara MY
    J Clin Invest; 2011 Jul; 121(7):2554-69. PubMed ID: 21670504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.
    Beres AJ; Haribhai D; Chadwick AC; Gonyo PJ; Williams CB; Drobyski WR
    J Immunol; 2012 Jul; 189(1):464-74. PubMed ID: 22649199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
    Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
    Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
    Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL; Atasoylu AA
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.
    Zeng M; Guinet E; Nouri-Shirazi M
    Transpl Immunol; 2009 Dec; 22(1-2):82-92. PubMed ID: 19635560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of graft-versus-host disease by double-negative regulatory T cells.
    Young KJ; DuTemple B; Phillips MJ; Zhang L
    J Immunol; 2003 Jul; 171(1):134-41. PubMed ID: 12816991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.